ArticleDigital health
NeurALLNet: An attention-based spiking neural network for energy-efficient multi-class classification of acute lymphoblastic leukemia.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The classification of Acute Lymphoblastic Leukemia (ALL) from peripheral blood smear images using Convolutional Neural Networks (CNNs) has achieved expert-level accuracy. However, the computational and memory requirements of CNNs pose a barrier to their deployment in resource-constrained clinical settings and low-income countries. To bridge this gap, we propose NeurALLNet, a memory-efficient convolutional spiking neural network (SNN) augmented with Squeeze-and-Excitation channel attention for the multi-class classification of ALL subtypes. Methods: NeurALLNet leverages sparse, event-driven temporal computation with an ultra-compact architecture of approximately 0.3M trainable parameters. The model was trained and evaluated on a primary dataset of ALL peripheral blood smear images, and its clinical generalizability was rigorously validated on an unseen external cohort of 3,242 images without retraining. We conducted hardware profiling on CPU and GPU platforms, alongside ablation studies and Grad-CAM visual explanations, to evaluate deployment viability and interpretability. Results: NeurALLNet achieved a test accuracy of 98.16% on the primary dataset, with a bootstrapped 95% Confidence Interval (CI) of [0.9663, 0.9939]. On the external validation cohort, it yielded an accuracy of 96.02%, with a robust 95% CI of [0.9534, 0.9667]. The architecture requires a memory footprint of 1.35 MB, achieving single-image inference latencies of 454.67 ms on a standard CPU and 11.24 ms on a GPU. Ablation studies confirmed that the attention mechanism is critical to the network's discriminative power, and Grad-CAM visualizations verified that predictions are grounded in clinically relevant morphological features. Conclusion: Compared to recent state-of-the-art ensemble and hybrid CNNs that require millions of parameters, NeurALLNet delivers competitive diagnostic accuracy while reducing the computational footprint by orders of magnitude. By providing this precision within a 1.35 MB envelope, NeurALLNet offers a scalable, energy-efficient digital health intervention suitable for portable Lab-on-a-Chip devices and point-of-care diagnostics worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.